KADCYLA® (trastuzumab emtansine), educational information for healthcare professionals. Information on an important potential risk: "medication error

17.03.2026 308 views

КАДСІЛА®(трастузумаб емтансин), освітня інформація для медичних працівників. Інформація щодо важливого потенційного ризику: «помилка при застосуванні лікарського засобуPDF · 441 КБ

Завантажити

KADCYLA® (trastuzumab emtansine), educational information for healthcare professionals. Information on an important potential risk: "medication error

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

KADCYLA® (trastuzumab emtansine), educational information for healthcare professionals. Information on an important potential risk: "medication error

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration